1naresh
Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1nareshArray ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) )Table 2:Treatment outcomes
Overall Aspirin+Clopidogrel Group Aspirin+Ticagrelor Group P Value Nonavailable data 1 1 0 Primary outcome (%) 22 (9.4) 14 (9.9) 8 (8.6) .822 Secondary outcomes (%) Ischemic stroke 17 (7.2) 10 (7.0) 7 (7.5) >.999 Disabling stroke 8 (3.4) 4 (2.8) 4 (4.3) .716 Any death 4 (1.7) 3 (2.1)a 1 (1.1)b >.999 Safety outcome (%) 19 (8.1) 13 (9.2) 6 (6.5) .479 mRS (%) .484 0–2 227 (96.6) 136 (95.8) 91 (97.8) 3–6 8 (3.4) 6 (4.2) 2 (2.2) Medication change (%) 12 (5.1) 6 (4.2) 6 (6.5) .547